| Title |
Topical Retinoids in Acne Vulgaris
|
|---|---|
| Published in |
American Journal of Clinical Dermatology, September 2012
|
| DOI | 10.2165/0128071-200809060-00003 |
| Pubmed ID | |
| Authors |
Anja Thielitz, Harald Gollnick |
| Abstract |
Topical retinoids represent a mainstay of acne treatment because they expel mature comedones, reduce microcomedone formation, and exert anti-inflammatory effects. The first-generation retinoid tretinoin (all-trans retinoic acid) and the synthetic third-generation polyaromatics adapalene and tazarotene are approved for acne treatment by the US FDA, whereas topical tretinoin, isotretinoin (13-cis retinoic acid), and adapalene are accredited in Canada and Europe. Topical retinoids have a favorable safety profile distinct from the toxicity of their systemic counterparts. Local adverse effects, including erythema, dryness, itching, and stinging, occur frequently during the early treatment phase. Their impact varies with the vehicle formation, skin type, frequency and mode of application, use of moisturizers, and environmental factors such as sun exposure or temperature. The broad anti-acne activity and safety profile of topical retinoids justifies their use as first-line treatment in most types of non-inflammatory and inflammatory acne. They are also suitable as long-term medications, with no risk of inducing bacterial resistance, for maintenance of remission after cessation of initial combination therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 89 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 19% |
| Student > Ph. D. Student | 10 | 11% |
| Other | 8 | 9% |
| Student > Doctoral Student | 8 | 9% |
| Student > Bachelor | 8 | 9% |
| Other | 20 | 22% |
| Unknown | 18 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 13% |
| Biochemistry, Genetics and Molecular Biology | 6 | 7% |
| Agricultural and Biological Sciences | 6 | 7% |
| Chemistry | 5 | 6% |
| Other | 10 | 11% |
| Unknown | 21 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 October 2023.
All research outputs
#1,332,892
of 25,621,213 outputs
Outputs from American Journal of Clinical Dermatology
#76
of 1,076 outputs
Outputs of similar age
#7,836
of 187,320 outputs
Outputs of similar age from American Journal of Clinical Dermatology
#20
of 287 outputs
Altmetric has tracked 25,621,213 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,076 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.5. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,320 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 287 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.